At the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Bruker announced the introduction of the new IVD MALDI Sepsityper^TM kit and workflow with standard operating procedures for the rapid identification of microorganisms from positive blood culture bottles. The IVD kit is now labeled according to the European IVD directive EC/98/79, and is developed for use with the IVD MALDI Biotyper (IVD MBT) system for rapid MALDI-TOF mass spectrometry-based microbial identification.

The IVD MALDI Sepsityper kit enables a rapid and easy isolation and identification of microorganisms within minutes from positive blood culture bottles. Harvested microorganisms are processed and then identified using the IVD MALDI Biotyper. The identification assay from positive blood cultures is applicable to Gram-negative and Gram-positive bacteria, as well as to yeast. The IVD MALDI Biotyper reference library covers more than 2,000 different bacteria species and approximately 200 species of yeasts, including candida. This workflow is recommended and optimized for blood culture bottles without any charcoal supplements.

Overall, the IVD MALDI Sepsityper workflow takes approximately 30 minutes after gram-staining and extraction from a positive blood culture bottle to identification. It saves the day normally required for additional agar plate culturing, and it can also save an additional 8-12 hours, when compared to traditional biochemical identification after agar plate culturing.

The IVD MALDI Sepsityper workflow reduces the turnaround time provided by traditional workflows by typically 24 to 36 hours after a blood culture bottle becomes positive. The faster results provided by the IVD MALDI Sepsityper workflow aid the clinician in the management of blood stream infections. These earlier identification results, combined with antibiotic stewardship programs, can reduce healthcare costs substantially, and can improve patient outcomes, while also assisting in the fight against antibiotic resistance via reductions in the use of ineffective or expensive antibiotics. In contrast to pure nucleic acid amplification test (NAATs), blood cultures do not amplify biologically non-active DNA or cells, but only the most active and relevant microbial species. Moreover, the IVD MALDI Sepsityper workflow is untargeted and offers very broad microbial coverage of gram-negative and gram-positive bacterial species, as well as clinically relevant yeast species, including candida.

Dr. Cassie Pope, Consultant Clinical Scientist from St. George’s Hospital in London, UK, said: “The introduction of the BrukerMALDI  Sepsityper kit into our workflow has proved to be a decision that we are very pleased with, and that has resulted in clear benefits to the laboratory and our users. We implemented it for the identification of organisms in all blood cultures that have flagged as positive in the morning. This has reduced our time to identification by 24 hours, and allows us to provide a better service, and promotes timely prescription of appropriate narrow spectrum antimicrobials. This is valued by clinicians and they are now used to the improved service and earlier identification information. Our scientific staff enjoys using the kit, as it is easy to perform and provides identifications that they have confidence in, typically within 30 minutes.”

Dr. Nils Morgenthaler, Vice President for Medical Affairs for the Bruker      Daltonics Division, added: “We and our collaborators now have several      years of experience with the research-use-only (RUO) MALDI Sepsityper      workflow, and the feedback from our customers and collaborators has been      very positive. So far, 21 peer reviewed scientific publications have      evaluated this approach, in which the RUO MALDI Sepsityper      workflow has been shown to provide approximately 80% correct      identification at the species level, with the remaining 20% mostly      unidentified, and with essentially no relevant misidentifications at the      genus level. With further recent improvements and expansion in the IVD      MALDI Biotyper reference library, this already excellent      identification performance directly from blood culture is expected to      improve even further. The recent CE-labeling of the kit underlines      Bruker´s strategy to provide more and more workflows for clinical      routine use on the IVD MALDI Biotyper platform. We believe that      the IVD MALDI Sepsityper kit and workflow has the potential to      rapidly become the new gold standard in microorganism identification in      clinical microbiology directly out of positive blood cultures, due to      its very short TTR and broad bacteria and yeast species coverage.”